Pune, India — June 2025
DeepTek, a leading medical imaging AI company from India, has received a significant recommendation from the World Health Organization (WHO) for its Chest X-ray AI solution for TB screening. In its latest policy guidance, WHO recommended the solution as meeting the performance standards for Computer-Aided Detection (CAD) software used in tuberculosis screening across both community and facility-based screening settings.
This recommendation underscores the solution’s clinical reliability, global scalability, and real-world impact—making it one of the few AI tools globally validated for identifying presumptive TB cases rapidly and accurately, particularly in low-resource settings. In 2022, 10.6 million people were diagnosed with TB, with the highest burden seen in South-East Asia, Africa, and the Western Pacific. These regions often face a shortage of radiologists and fragmented screening systems, leading to delayed diagnosis and treatment. DeepTek’s Chest X-ray AI solution addresses this challenge head-on by delivering rapid analysis of chest -rays in under a minute—even in remote areas without internet connectivity—making early intervention possible at scale.
“This recommendation marks a significant step forward in our mission to scale early TB detection,” said Dr. Amit Kharat, CEO, Co-founder of DeepTek. “By nearly halving the cost of identifying TB cases, it not only strengthens healthcare economics but also enhances quality of life by enabling timely triaging—even in the subclinical stages of the disease.”
He added, “Our mission has always been to improve access, accuracy, and affordability in radiology. This recommendation is a powerful boost to our efforts and a strong validation of the impact we strive to make.”
DeepTek’s Chest X-ray AI solution is certified by both the US FDA and EU CE MDR. Beyond detecting tuberculosis, it identifies over 21 other critical lung abnormalities—including nodules, masses, and pneumothorax—making it highly versatile for public health programs and routine lung screenings. A key differentiator of our solution is its ability to interpret pediatric chest X-rays for children aged four and above.
DeepTek’s platform supports end-to-end patient management across the TB screening workflow. Digital X-ray machines are used to capture chest scans, which are analyzed by DeepTek’s AI engine to generate TB risk predictions in under a minute. The system operates seamlessly even in offline settings, with data securely synced to the cloud once connectivity is restored.
“A key strength of the platform is its commitment to Responsible AI. It continuously monitors real-world accuracy at each deployment site, helping identify AI accuracy drift, biases, or variations in its effectiveness” said Ms. Ritika Taki, who leads the Global Health Initiative at DeepTek. “Comprehensive analytics and dashboards provide program coordinators with deep insights into screening activity, outcomes, and operational performance across locations—enabling data-driven decisions and remote oversight at scale”.
To date, DeepTek’s solution has been deployed at over 800 sites worldwide and has already facilitated the screening of more than 2 million individuals. The recent WHO recommendation is expected to accelerate adoption by National TB Programs, Ministries of Health, NGOs, and CSR-led healthcare initiatives—strengthening collective efforts toward the global goal of a TB-free world.